Fig. 7

Elvitegravir does not affect glutamate receptor-mediated EPSCs or glutamate release probability in hippocampal neurons. Whole-cell recordings from mCherry- and ChRII-negative cells of postsynaptic AMPA a, b and NMDA c receptor-mediated EPSCs evoked with 0.7 ms light pulses in DIV 14–18 primary hipppocampal cultures. Traces in left panels show responses over the timecourse of experiments. Plots on the right show the data for all cells as paired observations connected by a line as well as the paired mean difference, plotted as a bootstrap distribution. Mean differences are depicted as dots with the 95% confidence intervals indicated by the vertical error bars. a The amplitude of the first AMPA EPSC response to a pair (100 ms interstimulus interval) of light pulses was unaffected by Elvitegravir (20 μM) application for 10 min (N = 11 cells, p = 0.469) or 20 min (N = 5 cells, p = 0.874). EPSCs were rapidly blocked by NBQX (5 μM) in a subset of cells (N = 8; p < 0.005). Insets show examples of paired EPSC recordings. b The paired pulse ratio (PPR) was quantified as the ratio of the amplitude of EPSC2 / EPSC1 and was not affected by Elvitegravir application for 10 min (N = 11 cells, p = 0.469) or 20 min (N = 5 cells, p = 0.260). c NMDA receptor-mediated EPSCs were recorded at +40 mV in a different set of neurons. Elvitegravir application for 20 min did not affect the amplitude of responses (N = 8 cells, p = 0.822), which were rapidly blocked by DL-APV (N = 8 cells, p < 0.005, two-sided permutation t-test)